As they develop databases of patients and how they have done with DCVax-L over time, and probably also actual tumor databases which can be analyzed, they will have an incredibly invaluable resource for guiding their own future research and likely will be avoid to update the vaccine with new synthetic targets to anticipate how tumors mutate after early or even late treatment and target those mutations preemptively.
They will be able to ride this platform directly to curing cancers in the future with much more effective versions of DCVax-L in my estimation.This is one reason why this platform has an inordinately incredible value that I hope we get credit for, but which a buyer may quietly recognize but not acknowledge. I articulated this early on as a tissue library of both cancer cells and also blood draws and the valuable data that likely could come from all of that. I wonder that LP and the team have never articulated this incredible value proposition, but I hope that they will at some point. If they treat huge numbers of patients with many different types of cancer, just the process that DCVax-L uses itself, not even the vaccine, but the process, may throw of giant value to advance the research.
Of course they would need to word their permissions properly and get that permission for research during the course of treatment. That the company may analyze and owns the tissue and blood, cells and blood markers it gathers from the patient and that they can use them to develop cures and advance research.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
AI
